


PRODUCT INFORMATION



Vortioxetine-d₈

Item No. 28163

CAS Registry No.: 2140316-62-5
Formal Name: 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine-2,2,3,3,5,5,6,6-d₈
MF: C₁₈H₁₄D₈N₂S
FW: 306.5
Chemical Purity: ≥98% (Vortioxetine)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₈); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vortioxetine-d₈ is intended for use as an internal standard for the quantification of vortioxetine (Item No. 23694) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Vortioxetine-d₈ is supplied as a solid. A stock solution may be made by dissolving the vortioxetine-d₈ in the solvent of choice, which should be purged with an inert gas. Vortioxetine-d₈ is soluble in chloroform.

Description

Vortioxetine is a multimodal serotonergic agent that acts as a serotonin (5-HT; Item No. 14332) reuptake inhibitor ($K_i = 1.6$ nM) and binds to the 5-HT_{1A}, 5-HT_{1B}, 5-HT_{3A}, and 5-HT₇ receptors (K_i s = 15, 33, 3.7, and 19 nM, respectively).¹ It also binds to the β_1 -adrenergic receptor ($K_i = 46$ nM). It acts as an antagonist at 5-HT_{3A} and 5-HT₇, a partial agonist at 5-HT_{1B}, and a full agonist at 5-HT_{1A} receptors. Vortioxetine is selective for the serotonin transporter (SERT) over the dopamine and norepinephrine transporters (IC_{50} s = 5.3, 890, and 140 nM, respectively). It has affinity for histamine H₂, melanocortin 4, β_2 -adrenergic, 5-HT_{2C}, and 5-HT₆ receptors with K_i values greater than 180 nM, but it is selective over the majority of targets in a panel of 75 ion channels, G protein-coupled receptors, enzymes, and transporters. Vortioxetine (5 or 10 mg/kg per day) increases 5-HT levels *in vivo* in rat brain and decreases occupancy at SERT. At acute and chronic doses of 5 mg/kg, but not 10 mg/kg, it increases the time mice spend in the center of the open field test, increases mobility in the forced swim test, and decreases the latency to feed in the novelty suppressed feeding test.² It also increases proliferation and survival of adult-born granule cells in the hippocampus. Formulations containing vortioxetine have been used in the treatment of major depressive disorder.

References

1. Bang-Andersen, B., Ruhland, T., Jørgensen, M., *et al.* Discovery of 1-[2-(2,4-dimethylphenyl)sulfanyl]phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. *J. Med. Chem.* **54**(9), 3206-3221 (2011).
2. Guilloux, J.P., Mendez-David, I., Pehrson, A., *et al.* Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. *Neuropharmacology* **73**, 147-159 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM